# STERIS plc Moat

Status: published. Policy: company-analysis-1.

STERIS has established sterilization, validation and equipment-service capabilities, substantial recurring demand and demonstrated pricing increases. These support potential switching costs and technical advantages, but the passages do not establish durable protection against competitors. This is insufficient moat evidence, rather than demonstrated competitive weakness. Recent AST volume declines and segment margin compression temper favorable growth and execution.

## switching_costs

Process-validation support and lifetime equipment servicing create opportunities for embedded customer relationships. These are current capabilities; the cost or difficulty of switching suppliers is not demonstrated.

Durability: Potentially extends across equipment lives and manufacturing processes, but customer renewal history, revalidation requirements and actual switching costs are undisclosed.

Risks: Maintenance agreements are generally cancellable without penalty. Customers can use competing service providers or sterilize in-house. Latest AST organic growth depended on pricing while volume declined.

Invalidation: The switching-cost hypothesis would fail if customers routinely transferred validated processes or equipment servicing to alternatives without material expense, disruption or loss of performance. Persistent customer departures following price increases would also undermine it.

Competitors: Sterigenics, BBraun, Crothall, Olympus, Pentax
## intangible_assets

STERIS possesses technical know-how, a substantial patent portfolio and operating capabilities in regulated sterilization markets. Their existence is evidenced; superior customer outcomes or exclusion of competitors is not.

Durability: Technical expertise and intellectual property may support differentiation, but patent counts do not establish economically important protection, remaining useful life or durable pricing premiums.

Risks: STERIS describes intellectual-property protection as limited and competition as intense. Innovation can displace existing offerings, while its impaired internally developed accelerator demonstrates that development spending can fail.

Invalidation: The technical-advantage hypothesis would fail if alternatives consistently matched performance and compliance at lower total cost, or if important patents proved unenforceable or commercially irrelevant and customers migrated.

Competitors: Sterigenics, Belimed, Contec, Ecolab, Fedegari, Getinge, Stilmas
- [https://www.sec.gov/Archives/edgar/data/1757898/000162828026039136/ste-20260331.htm](https://www.sec.gov/Archives/edgar/data/1757898/000162828026039136/ste-20260331.htm) · 2026-05-29
- [https://www.sec.gov/Archives/edgar/data/1757898/000162828026054830/ste-20260630.htm](https://www.sec.gov/Archives/edgar/data/1757898/000162828026054830/ste-20260630.htm) · 2026-08-07
- [https://www.sec.gov/Archives/edgar/data/1757898/000119312526267599/d142920ddef14a.htm](https://www.sec.gov/Archives/edgar/data/1757898/000119312526267599/d142920ddef14a.htm) · 2026-06-11
- [https://www.sec.gov/Archives/edgar/data/1757898/000175789825000005/ste-20250331.htm](https://www.sec.gov/Archives/edgar/data/1757898/000175789825000005/ste-20250331.htm) · 2025-05-29
- [https://www.sec.gov/Archives/edgar/data/1757898/000175789824000008/ste-20240331.htm](https://www.sec.gov/Archives/edgar/data/1757898/000175789824000008/ste-20240331.htm) · 2024-05-29
- [https://www.sec.gov/Archives/edgar/data/1757898/000162828026006055/ste-20251231.htm](https://www.sec.gov/Archives/edgar/data/1757898/000162828026006055/ste-20251231.htm) · 2026-02-06
- [https://www.sec.gov/Archives/edgar/data/1757898/000162828026053412/ste6302026ex991.htm](https://www.sec.gov/Archives/edgar/data/1757898/000162828026053412/ste6302026ex991.htm) · 2026-08-05
- [https://www.sec.gov/Archives/edgar/data/1757898/000162828026033580/ste03312026ex991.htm](https://www.sec.gov/Archives/edgar/data/1757898/000162828026033580/ste03312026ex991.htm) · 2026-05-11
- [https://www.sec.gov/Archives/edgar/data/1757898/000119312526212159/d27562dex991.htm](https://www.sec.gov/Archives/edgar/data/1757898/000119312526212159/d27562dex991.htm) · 2026-05-07
- [https://www.steris.com/about/terms_sale](https://www.steris.com/about/terms_sale) · 2026-10-19
- [https://www.sec.gov/Archives/edgar/data/1757898/000119312526338137/d141533d8k.htm](https://www.sec.gov/Archives/edgar/data/1757898/000119312526338137/d141533d8k.htm) · 2026-08-06
- [https://www.sec.gov/Archives/edgar/data/1757898/000119312526212159/d27562d8k.htm](https://www.sec.gov/Archives/edgar/data/1757898/000119312526212159/d27562d8k.htm) · 2026-05-07
- [https://www.sec.gov/Archives/edgar/data/1757898/000119312526143973/d115941d8k.htm](https://www.sec.gov/Archives/edgar/data/1757898/000119312526143973/d115941d8k.htm) · 2026-04-06
- [https://www.sec.gov/Archives/edgar/data/31462/000110465926018357/ecl-20251231x10k.htm](https://www.sec.gov/Archives/edgar/data/31462/000110465926018357/ecl-20251231x10k.htm) · 2026-02-23

[JSON](https://beanvest.com/stock/ste/moat.json)